← All trials
NCT03650036
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 4, 2018
- Primary completion
- Dec 21, 2018
- Completion date
- Jun 4, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 86
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Federal University of PiauiLead sponsor
- Federal University of PiauiReponsible party - principal investigator
- Federal University of PiauiOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.